Top FDA Officials, Compromised by Conflicts of Interest
Two high ranking FDA officials’ conflicts of interest have led one to resign, the other is under investigation by the Inspector General of the Department of Health and Human Services:
Two high ranking FDA officials’ conflicts of interest have led one to resign, the other is under investigation by the Inspector General of the Department of Health and Human Services:
Essentially PhRMA won the right to continue bilking the beleaguered American taxpayer–a concession won under the Bush Administration which prohibited Medicare to negotiate prescription drug prices.
In 2006, PREPA was passed due to fear of an avian flu pandemic, in the event the avian
flu virus mutated to enable person-to-person spread. Avian flu then had a 70% death rate.
ACRE’s mission is to persuade physicians that MORE rather than less industry involvement in Continuing Medical Education programs is good for patients–much as industry’s "Harry and Louise" ads were aimed at convincing the public that universal healthcare was BAD for them.
…an aggressive campaign to vaccinate against the swine flu–EVEN BEFORE THE VACCINE’S SAFETY HAS BEEN TESTED, or the safety of the vaccine adjuvants have been tested.
Unless the overall treatment and services provided to schizophrenia patients in Finland is unique and especially protective—which the authors do not suggest—their claimed findings of lowered mortality rates for antipsychotic drug users are belied by a consistent body of evidence.
Motherhood is NOT a Medical Disorder Stop: Mother’s Act
So far as I can tell, the panel that I was asked to participate in was the only one that focused on the pharmaceutical industry.
The study, reported in The Journal of the American Medical Association, "found no evidence of an association between the serotonin gene and the risk of depression, no matter what people’s life experience was."
Psychiatry’s leadership is scrambling and fumbling in its effort to explain why it’s collusion with industry for pay is okay.
Two important analyses in Open Medicine , a peer-reviewed, independent, open-access journal, focus on methodological flaws in data analysis of randomized drug trials.
Forbes Magazine reports "How one company turned a rejection into a thumbs up, and what it could mean for the drug industry as a whole."